Vestcor Inc trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 12.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,507 shares of the company’s stock after selling 645 shares during the period. Vestcor Inc’s holdings in Medpace were worth $1,497,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new stake in shares of Medpace in the 3rd quarter worth approximately $276,000. KBC Group NV increased its stake in Medpace by 5.5% during the 3rd quarter. KBC Group NV now owns 1,213 shares of the company’s stock valued at $405,000 after purchasing an additional 63 shares in the last quarter. Natixis Advisors LLC purchased a new position in Medpace in the third quarter worth about $3,754,000. Mutual of America Capital Management LLC lifted its stake in shares of Medpace by 1.9% in the third quarter. Mutual of America Capital Management LLC now owns 13,738 shares of the company’s stock worth $4,586,000 after buying an additional 255 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in shares of Medpace by 61.3% during the third quarter. Thrivent Financial for Lutherans now owns 14,430 shares of the company’s stock valued at $4,817,000 after buying an additional 5,484 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.
Medpace Trading Up 2.2 %
Shares of MEDP opened at $324.95 on Friday. The firm has a fifty day simple moving average of $340.28 and a two-hundred day simple moving average of $341.12. The firm has a market cap of $9.90 billion, a PE ratio of 25.73, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77.
Wall Street Analyst Weigh In
Separately, Robert W. Baird boosted their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $381.44.
View Our Latest Stock Analysis on Medpace
About Medpace
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
See Also
- Five stocks we like better than Medpace
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the Dow Jones Industrial Average (DJIA)?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.